Stockscreener 앱 받기
1.70
7.10%
-0.13
시간 외 거래:
1.72
0.02
+1.18%
전일 마감가:
$1.83
열려 있는:
$1.85
하루 거래량:
69,094
Relative Volume:
0.05
시가총액:
$5.66M
수익:
$35.75M
순이익/손실:
$11.57M
주가수익비율:
-0.4466
EPS:
-3.8069
순현금흐름:
$-26.25M
1주 성능:
-10.53%
1개월 성능:
+12.58%
6개월 성능:
-38.85%
1년 성능:
-79.01%
1일 변동 폭
$1.69
$1.8952
1주일 범위
$1.69
$2.16
52주 변동 폭
$1.06
$9.00
레드힐 바이오파마 ADR Stock (RDHL) Company Profile
명칭
Redhill Biopharma Ltd Adr
전화
-
주소
-
RDHL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.70 | 6.09M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
141.09 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
439.99 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
레드힐 바이오파마 ADR Stock (RDHL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-08-31 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-18 | 개시 | H.C. Wainwright | Buy |
| 2020-09-11 | 개시 | BTIG Research | Buy |
| 2019-07-12 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | 개시 | Nomura | Buy |
| 2017-10-06 | 개시 | Seaport Global Securities | Buy |
| 2017-10-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-24 | 재확인 | FBR & Co. | Outperform |
| 2016-07-27 | 재확인 | FBR Capital | Outperform |
| 2015-09-29 | 개시 | Nomura | Buy |
| 2015-07-29 | 재확인 | ROTH Capital | Buy |
| 2015-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-15 | 재확인 | ROTH Capital | Buy |
모두보기
레드힐 바이오파마 ADR 주식(RDHL)의 최신 뉴스
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - PR Newswire
RedHill Biopharma stock surges after court upholds $10M judgment - Investing.com
RedHill Biopharma stock surges after court upholds $10M judgment By Investing.com - Investing.com South Africa
Is RDHL Poised for Rebound? Analyzing Financial Moves - StocksToTrade
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo - Sahm
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights - Placera.se
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million - PR Newswire
RedHill Biopharma receives Nasdaq extension to regain compliance by October - Investing.com South Africa
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com India
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress - Finansavisen
Taking the lead: Redhill Biopharma Ltd. ADR (RDHL) - Sete News
The time has not yet come to remove your chips from the table: Hertz Global Holdings Inc (HTZ) - Sete News
A significant driver of top-line growth: Alexandria Real Estate Equities Inc (ARE) - Sete News
Redhill Biopharma Ltd. ADR [RDHL] Insider Activity: An Update for Investors - knoxdaily.com
RedHill Biopharma faces Nasdaq non-compliance issue - Investing.com
RedHill Biopharma faces Nasdaq non-compliance issue By Investing.com - Investing.com India
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com
Redhill Biopharma Ltd. ADR (RDHL)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
Hyloris secures global rights to RedHill's RHB-102 - Investing.com
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published - PR Newswire
Talicia® Launched in the United Arab Emirates - PR Newswire
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - PR Newswire
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
Phil and RedHill Biopharma Partner to Increase Access to Talicia® - Business Wire
RedHill Biopharma to Implement ADS Ratio Change to 1:400 By Investing.com - Investing.com India
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - PR Newswire UK
RedHill presents New Talicia® and Movantik® data analyses at ACG 2022 - EurekAlert!
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates - PR Newswire
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 - BioSpace
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans - Stock Titan
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
S&W Seed Company (SANW): How Does It Stack Up Against Its Peers? - Insider Monkey
RedHill Biopharma files for further Nasdaq offering - גלובס
Redhill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
레드힐 바이오파마 ADR (RDHL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
1.16%
자본화:
|
볼륨(24시간):